We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
04 May 2021 - 07 May 2021
Virtual Venue

Multiplex Bead-Based Immunoassay Validated for Non-Invasive Bladder Cancer Detection

By LabMedica International staff writers
Posted on 04 Jan 2021
Print article
Image: Oncuria is a simple urine test that detects and analyzes multiple tumor protein biomarkers for improved bladder cancer detection (Photo courtesy of Nonagen Bioscience Corporation).
Image: Oncuria is a simple urine test that detects and analyzes multiple tumor protein biomarkers for improved bladder cancer detection (Photo courtesy of Nonagen Bioscience Corporation).
Cancer of the urinary bladder has two unique features: the tumor is continuously immersed in a urine and the tumor is able to shed cells or release tumor associated products (e.g., protein, DNA, RNA) directly into urine, which is easily collected and assessed.

Though urine is largely considered a harsh environment with varying pH and high salt levels, products associated with bladder tumors within the urine have been shown to correlate with their presence within the actual bladder tumor. Promising diagnostic biomarkers included nuclear matrix protein 22 (NMP-22) and bladder tumor antigen (BTA). Unfortunately, these tests suffer from high false-positive rates.

A multidisciplinary team of scientists collaborating with Cedars-Sinai Medical Center (Los Angeles, CA, USA) assessed the analytical performance of a multiplex assay called Oncuria (Nonagen Bioscience Corporation, Los Angeles, CA, USA) to quantify protein biomarkers towards a bladder cancer associated diagnostic signature in voided urine. The team used Luminex xMAP technology (Luminex Corporation, Austin, TX, USA), to measure the concentrations of 10 urinary analytes: angiogenin, (ANG); apolipoprotein E, (APOE); alpha-1 antitrypsin, (A1AT); carbonic anhydrase 9,(CA9); interleukin 8, (IL8); matrix metallopeptidase 9, (MMP9); matrix metallopeptidase 10, (MMP10); plasminogen activator inhibitor 1, (PAI1); syndecan 1, (SDC1); vascular endothelial growth factor, (VEGF).

The scientists reported that their analytical evaluation demonstrated a) all antigen cross-reactivity was noted to be <1% of the tested concentration, b) minimal detected dose ranged from 0.295 pg/mL in IL8 to 31.1 pg/mL in APOE, c) highly reproducible and accurate noting coefficient of variation (CV) and relative error (RE) values below 15% for all analytes and d) minimal interference. The assay can be completed in less than five hours using as little as 150 μL of voided urine.

The authors concluded that Oncuria is the first multiplex bead-based immunoassay for the non-invasive detection of bladder cancer that has been analytically validated as a tool with the potential to help clinicians manage patients at risk of harboring bladder cancer. They believe that this assay, unlike most urine-based diagnostic assays, is well suited to identify patients who may require additional testing to rule in the presence of a bladder tumor. Implementing the assay clinically is a necessary first step to improve on current diagnostic approaches and to demonstrate the clinical utility of advanced molecular diagnostic testing. The study was published on November 13, 2020 issue of the journal Practical Laboratory Medicine.

Related Links:
Cedars-Sinai Medical Center
Nonagen Bioscience Corporation
Luminex Corporation


Gold Supplier
Clinical Chemistry Series
Clinical Chemistry Series
Laboratory Automation Solution
SATLAS-TCA
New
Gold Supplier
SARS-CoV-2 Antibody Test
SARS-CoV-2 UTAB FS
COVID-19 Anitibody Test
SGTi-flex COVID-19 IgM/IgG

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Oxylipin biosynthesis reinforces cellular senescence and allows detection of senolysis (Photo courtesy of Dr. Christopher Wiley)

Novel Lipid Biomarker Detects Senescent Cells

A recent paper identified a lipid biomarker indicative of cellular senescence and described a method to evaluate its effect on the molecular events that lead to senescence. Cellular senescence is a... Read more

Industry

view channel
Image: The Luminex Aries® System (Photo courtesy of Luminex Corporation)

DiaSorin to Acquire Luminex to Broaden Positioning in Molecular Diagnostics Space

DiaSorin S.p.A. (‎Saluggia‎, Italy) has announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation (Austin, TX,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.